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Abstract
Cardiovascular events are a major cause of morbidity and mortality in kidney transplant
recipients. We conducted a retrospective study using healthcare databases in Ontario, Canada
to determine whether the incidence of cardiovascular events has changed from 1994 to 2009
in 4954 kidney transplant recipients. Our primary endpoint was a 3-year composite outcome
of post-transplant death or cardiovascular event (myocardial infarction, percutaneous
coronary intervention, coronary artery bypass graft, or stroke). Recipients were older and had
more baseline co-morbidity in recent eras (1994-1997 vs. 2006-2009: median age 45 vs. 53
years; coronary artery disease 22% vs. 37%). A total of 445 recipients (9.0%) died or
experienced a cardiovascular event within 3 years. There was no significant change in the
composite outcome or death-censored cardiovascular events (p=0.41 and 0.92, respectively)
over time. Despite transplant centers accepting recipients who are older with more comorbidities, the incidence of death or cardiovascular event has remained stable.

Keywords
administrative data, cardiovascular disease, coronary artery bypass graft, health outcomes,
kidney transplant recipients, myocardial infarction, percutaneous coronary intervention,
retrospective cohort study, stroke, trends.
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Chapter 1 : Introduction

1.1 Background
Compared to dialysis, kidney transplantation improves survival.(1–3) Cardiovascular
disease accounts for 30% of deaths with a functioning graft and remains the primary
cause of death in kidney transplant recipients.(4) As described in recent clinical practice
guidelines, kidney transplant recipients are a high-risk group for cardiovascular
disease.(5,6) For example, in a retrospective study of 36,000 kidney transplant recipients
between 1995 and 2000 identified in the United States Renal Data System (USRDS)
database, 1 in 10 first-time kidney transplant recipients (11%) had a myocardial
infarction in the subsequent 3 years.(7) In recent years, a greater proportion of individuals
receiving kidney transplants are older and have more co-morbidities, including pretransplant cardiovascular disease and diabetes mellitus.(8) We conducted this study to
assess whether these secular changes have resulted in an increased risk of cardiovascular
events after kidney transplantation over time.

1.2 Objectives
The specific aims of this research project were as follows:
1) To describe the secular trends in the 3-year cumulative incidence of death or first
major cardiovascular event after receiving a kidney transplant for recipients from
1994 to 2009.
2) To describe the secular trends in the individual components of the above composite
outcome, specifically, the 3-year cumulative incidence of a) death and b) deathcensored major cardiovascular event in kidney transplant recipients.
3) To compare the above trends in the kidney transplant recipient population to that in
the general population over the same time period.

2

Chapter 2 : Literature Review

2.1 Chronic Kidney Disease (CKD)
In 2002, the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative
(NKF-KDOQI) developed a definition and classification system for chronic kidney
disease (CKD).(9) In these guidelines, CKD was defined based on the presence of kidney
damage due to structural or functional abnormalities and/or kidney dysfunction as
measured by a glomerular filtration rate (GFR) of <60 mL/min/1.73 m2 for at least 3
months (Table 1).

Table 1: Stages of chronic kidney disease.a
Stage

Description

GFR (mL/min/1.73 m2)

1

Kidney damage with normal or high GFR

≥90

2

Kidney damage with mild decrease in GFR

60-89

3

Moderate decrease in GFR

30-59

4

Severe decrease in GFR

15-29

5
Kidney failure
<15 (or RRT)
Adapted from the NKF-KDOQI guidelines.(9)
Abbreviations: GFR, glomerular filtration rate; NKF-KDOQI, National Kidney
Foundation-Kidney Disease Outcomes Quality Initiative; RRT, renal replacement
therapy.
a
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2.2 End-Stage Renal Disease (ESRD)
Definition of ESRD
End-stage renal disease (ESRD) (CKD Stage 5) is defined as either a GFR of
<15 mL/min/1.73 m2 or the need for renal replacement therapy (RRT; see Section 2.3) for
symptoms or complications of kidney failure (Table 1).(9) The Canadian Organ
Replacement Register (CORR) collects information on patients with kidney failure and
their subsequent treatments.(10) CORR defines ESRD as patients who receive treatment
for their kidney failure with either ongoing dialysis or a kidney transplant.

Epidemiology of ESRD
Prevalence is defined as the number of total cases at a point in time divided by the size of
the overall population. Incidence is defined as the number of new cases during a given
period divided by the size of the at-risk population. The rate per million population
(PMP) per year is calculated as (number of cases / population) x 1,000,000.
According to CORR, in 2012, there were 41,252 prevalent cases of ESRD in
Canada and this number has increased by 40% from 29,540 in 2003.(10) Older patients
(≥65 years old) represent approximately 40% of prevalent cases of ESRD and the
proportion of males is 60%. Diabetes mellitus remains the primary cause of ESRD (27%)
followed by glomerulonephritis (i.e. inflammation of the kidneys usually due to an
immunological disease; 22%).
In 2012, there were 5431 incident cases of ESRD for an incidence rate of 156
PMP.(10) Although the incidence rate is higher than it was in 1993 (incidence rate of 101
PMP), it has remained stable over the last decade (in 2003, incidence rate was 162 PMP).
Older patients (≥65 years old) represent more than half of new cases each year. The
primary cause of ESRD is diabetes mellitus accounting for approximately 38% of new
cases, followed by renal vascular diseases (15%) such as hypertension.
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2.3 Renal Replacement Therapy (RRT)
Definition of RRT
The treatment for patients with kidney failure is commonly referred to as renal
replacement therapy (RRT). The most common form of RRT is dialysis, which consists
of either hemodialysis or peritoneal dialysis. Dialysis acts as an artificial kidney,
removing waste products and excess water from the body. The second form of RRT is
kidney transplantation for which the organ can be from either a living donor or a
deceased donor.

Epidemiology of RRT
Overall, in 2012, the proportion of patients with ESRD on dialysis was 58% (n=23,814)
of which approximately 50% were on hemodialysis and 10% were on peritoneal
dialysis.(10) The remaining 42% (n=17,438) of patients with ESRD had a functioning
kidney transplant and this rate has increased from 222 PMP in 1993 to 500 PMP in 2012.
The proportions of patients on dialysis (approximately 60%) or with a functioning kidney
transplant (approximately 40%) have not changed dramatically in the last decade. The
highest number of kidney transplant surgeries in Canada is performed in Ontario.
The majority of patients who start treatment for their ESRD are initiated on
hemodialysis (79%), followed by peritoneal dialysis (18%), then pre-emptive kidney
transplantation (i.e. receipt of a kidney transplant without receiving dialysis first;
3%).(10) In Canada, these proportions have remained fairly stable over time from 2003 to
2012.
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2.4 Outcomes in Dialysis Versus Kidney Transplantation
There have been many studies comparing the different types of RRT and survival for
patients with ESRD.(1–3,11) In a longitudinal study by Wolfe et al., kidney transplant
recipients in the United States (U.S.) had a 2.8-fold higher relative risk of death in the
first 2 weeks of their surgery compared to patients who remained on the waiting list for a
transplant.(1) This was likely due to peri-operative surgical risks as well as risks
associated with initial high-dose immunosuppression used for induction and maintenance
therapy. At 18 months, the relative risk of death in kidney transplant recipients compared
to patients on the waiting list was significantly lower (relative risk 0.32; 95% confidence
interval [CI] 0.30 to 0.35; p<0.001). The survival benefit was observed across all ages
(including older recipients), both sexes, all races, and for all causes of ESRD but was
greatest amongst recipients who were younger, Caucasian, or had diabetes mellitus as the
cause of their ESRD. Similar results were observed in a cohort of patients with ESRD
from Ontario, Canada.(3) The 5-year patient survival is higher with a kidney from a
living donor (94%) than with a kidney from a deceased donor (76%) and both are higher
than remaining on chronic dialysis (60%). In addition to greater long-term survival,
kidney transplantation is also associated with improved quality of life and lower
healthcare costs compared to remaining on dialysis.(12–16) For all these reasons, in
eligible patients with ESRD, kidney transplantation is the preferred treatment modality.

2.5 Cardiovascular Disease in Kidney Transplant
Recipients
While the risk of cardiovascular death is significantly lower with kidney transplantation
compared to dialysis, the risk remains higher than the general population even after
stratifying by age, sex, and race.(17,18) According to the 2014 United States Renal Data
System (USRDS) Annual Report, cardiovascular disease remains the primary identified
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cause of death in kidney transplant recipients.(4) It accounts for almost 30% of deaths
with a functioning graft.
Unfortunately, there is limited information regarding the incidence of non-fatal
cardiovascular events post-transplantation. One study using the USRDS followed almost
36,000 kidney transplant recipients between 1995 to 2000 and found that the 3-year
cumulative incidence of post-transplant myocardial infarction was 11%.(7) The
occurrence of a myocardial infarction predicted graft failure (hazard ratio 1.9; 95% CI 1.6
to 2.2) and death.
Another study using the USRDS compared female kidney transplant recipients
between 1987 to 1994 whose ESRD was due to lupus nephritis (n=946), diabetes mellitus
(n=5173), or other causes (n=12,733).(19) After a median follow-up of 2.5 years, and
after adjusting for age and race, the incidence rate of post-transplant myocardial
infarction was similar in women with lupus nephritis as their cause of ESRD compared to
women with other causes for ESRD (5.7 per 1000 patient-years for women with lupus
nephritis vs. 3.1 per 1000 patients years for women with other causes; adjusted hazard
ratio [aHR] 1.67; 95% CI 0.86 to 3.23; p=0.13). The adjusted incidence rate was highest
in women with diabetes mellitus as their cause of ESRD compared to women with other
causes for ESRD (10.0 per 1000 patient-years; aHR 3.31; 95% CI 2.59 to 4.22;
p<0.0001). These incidence rates in kidney transplant recipients were lower than in the
women who remained on dialysis.
Another retrospective cohort study using the Netherlands Organ Transplantation
Registration database followed 2187 kidney transplant recipients between 1984 to 1997
and reported that the cumulative incidence of post-transplant cardiovascular events
(myocardial infarction, percutaneous coronary intervention, coronary artery bypass
grafting, cerebrovascular accident, and cardiovascular death) was 40%.(20) The
incidence of cardiovascular events was highest in the first 3 months after transplantation
(4%). Although the median follow-up was 8 years (interquartile range 4.5 to 11.4), this
study only included recipients transplanted before 1997 and may not reflect current
patient characteristics or clinical practice patterns.
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Similarly, a smaller study from Germany compared 46 patients with type I
diabetes mellitus who received a kidney transplant between 1978 to 1997 to 46 patients
with type I diabetes mellitus who were on the waiting list for a transplant but remained on
hemodialysis.(11) Recipients and dialysis patients were matched 1:1 on age, sex, duration
of diabetes mellitus, dialysis vintage (duration on dialysis), and waitlist duration. After a
mean follow-up time of 6 years, kidney transplant recipients had a significantly lower
risk of myocardial infarction (9% vs. 28%; odds ratio [OR] 0.24; 95% CI 0.07 to 0.81;
p=0.03) and coronary angioplasty (9% vs. 33%; OR 0.20; 95% CI 0.06 to 0.65; p=0.008)
compared to hemodialysis patients.

2.6 Cardiac Risk Factors in Kidney Transplant Recipients
Kidney transplant recipients have a unique combination of traditional cardiovascular risk
factors and renal-specific cardiovascular risk factors.(21) Traditional cardiovascular risk
factors include hypertension, diabetes mellitus, hyperlipidemia, smoking, older age,
obesity, and physical inactivity.(22) Renal-specific associative factors include decreased
renal function (compared to the general population), immunosuppressive medications,
episodes of rejection and graft loss, and donor type (living versus deceased
donors).(20,23,24) These factors are often interrelated and thus, it can be difficult to
isolate the effects of a single risk factor on cardiovascular outcomes. For example,
although a kidney transplant improves the recipient’s renal function, there is often
residual renal impairment that can cause or exacerbate other cardiovascular risk factors
such as hypertension.(21) In some studies, decreased renal function has been shown to be
an independent risk factor for cardiovascular disease.(25–28) Similarly, long-term
immunosuppressive medications, such as steroids and calcineurin-inhibitors, used to
prevent and treat rejection may cause or worsen hypertension, diabetes mellitus, and renal
impairment.(23) For these reasons, the Kidney Disease: Improving Global Outcomes
(KDIGO) guidelines suggest that kidney transplant recipients be considered to be at the
highest risk for cardiovascular disease.(5)
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2.7 Secular Trends in Cardiovascular Disease
There have been several advances in the screening and management of cardiovascular
disease in the CKD population.(29) In addition to this, the baseline characteristics of
accepted recipients has changed over time.(8,30) Unfortunately, there is a lack of
literature regarding how these secular changes have affected cardiovascular outcomes
after kidney transplantation. One study from 2001 used the USRDS to follow a cohort of
104,000 patients on the kidney transplant waiting list between 1988 to 1996, of which
73,707 patients subsequently received a transplant.(31) For transplanted patients, the 5year annual adjusted cardiovascular death rate per 1000 patients decreased linearly from
19.2 in 1989 to 9.1 in 1996. A similar trend for cardiovascular death was seen in
waitlisted patients (65 in 1989 to 46 in 1996) and in the general population (1.6 in 1989
to 1.3 in 1996). Thus, cardiovascular death in kidney transplant recipients improved over
the study period and was lower than those on the waitlist, although it still remained
higher than the general population.
In 2007, another study using the Australia and New Zealand Dialysis and
Transplant (ANZDATA) registry reported trends over time in 6764 kidney transplant
recipients.(8) From 1993 to 2004, there was a trend towards older recipients, higher
recipient body mass index, and longer waiting time in recent cohorts. There was also a
significant increase in baseline recipient co-morbidities including cardiovascular disease
and diabetes mellitus (assessed at the start of renal replacement therapy). As in the
previous study, cardiovascular death decreased over time, despite the increase in recipient
cardiovascular co-morbidities, likely due to improved management over time of
cardiovascular risk factors and outcomes. In both studies, the outcome of non-fatal
cardiovascular events was not reported.
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2.8 Limitations of the Current Literature
Given the significance of cardiovascular disease in the kidney transplant population,
information regarding secular trends in cardiovascular outcomes and clinical practices
would better inform transplant centers and patients. Unfortunately, there are major
knowledge gaps in the literature and prior studies have significant limitations:
1) Much of the literature on cardiovascular outcomes using transplant registries focuses
on cardiovascular mortality rather than non-fatal cardiovascular events. We know little
about the secular trends in non-fatal cardiovascular events in the kidney transplant
population despite the increase in recipient cardiovascular co-morbidities over time.(31)
2) Pre-transplant baseline co-morbidities are often inadequately captured.(8)
3) Previous studies prior to 2000 have a cohort of recipients that may not be
representative of the current kidney transplant population.(30)
4) The largest studies assessing cardiovascular outcomes have used the USRDS (U.S.
data) and there is a need to understand the trends in a Canadian kidney transplant
population.(7,31)
Ontario residents receive universal access to hospital and physician services and coverage
for medical services are from a single provincial payer system. The unique linked
healthcare administrative databases at the Institute for Clinical Evaluative Sciences
(ICES) can be used to generate new information that addresses the limitations of previous
studies described above. This comprehensive administrative database has been used in
previous studies to assess trends in renal and cardiovascular outcomes and its strengths
are internationally recognized.(32,33)

10

Chapter 3 : Methodology

3.1 Design and Setting
We conducted a population-based retrospective cohort study using linked healthcare
databases via unique, encoded identifiers held at the Institute for Clinical Evaluative
Sciences (ICES) in Ontario, Canada. Ontario is the most populous Canadian province
with approximately 13 million residents who all have universal access to hospital care
and physician services. The reporting of this study follows guidelines set out for
observational studies (Appendix 2)(34), and was conducted according to an established
protocol approved by the research ethics board at Sunnybrook Health Sciences Centre
(Toronto, Canada).

3.2 Data Sources
We ascertained baseline characteristics, covariate information, and outcome data from
records in 4 databases.

Canadian Organ Replacement Register (CORR) Database
Kidney transplant recipients were identified from the CORR database that captures all
dialysis and kidney transplant activity in Canada. Compared to information collected at
the transplant centers, CORR accurately identified kidney transplant recipients with a
sensitivity of 96% (95% confidence interval [CI] 94% to 97%) and a positive predictive
value of 98% (95% CI 98% to 99%).(35)
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Registered Persons Database (RPDB)
The RPDB captured demographic information such as date of birth, sex, postal code, and
vital status (such as death).

Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD)
Diagnostic and procedural information during hospital admissions was gathered from the
CIHI-DAD. Coding of primary and secondary diagnoses and inpatient procedures used
the 9th version of the International Classification of Disease Canadian Modified system
(ICD-9 CM) prior to 2002 and the 10th version, Canada (ICD-10 CA) for all diagnoses
after 2002. We used this database to determine co-morbid conditions prior to
transplantation, assess cardiovascular outcomes, and identify potential confounders.

Ontario Health Insurance Plan (OHIP) Database
Physicians in Ontario may submit billing claims for reimbursement to the OHIP using
diagnostic and fee codes for every inpatient, outpatient, and laboratory service rendered
to a patient. We used this database to ascertain our primary outcome of cardiovascular
events.

These databases have been used extensively for research on health outcomes and services
including studies on cardiovascular disease.(32,36–43) The majority of the data were
complete with the exception of income (0.3% missing), donor status (1% missing),
primary cause of end-stage renal disease (ESRD, 8% missing), and race (10% missing).
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3.3 Population: Kidney Transplant Recipients
We included all adult recipients who were permanent residents of Ontario and received
their first kidney-only transplant between January 1, 1994 and December 31, 2009 from 1
of the 6 major transplant centers in Ontario. The 6 major transplant centers included
London Health Sciences Centre, St. Joseph’s Healthcare System (Hamilton), University
Health Network (Toronto), St. Michael’s Hospital (Toronto), Kingston General Hospital,
and Ottawa General Hospital. Only those kidney transplants performed at The Hospital
for Sick Children (Toronto) were excluded from the study since our study population
only consisted of adult kidney transplant recipients. The date of their transplant served as
the start date for follow-up and was designated the ‘index date’. The year of kidney
transplantation represented the primary exposure of interest.
We excluded pediatric recipients (<18 years old) at the time of transplant and
those who had received a previous organ transplant or a simultaneous multi-organ
transplant, including kidney-pancreas. Multi-organ transplants are uncommon compared
to single-organ transplants, with simultaneous kidney-pancreas transplantation
comprising only 4% of all kidney transplantations done in Ontario in the last 10
years,(10); cardiovascular outcomes also differ in this population compared to kidneyonly transplantation.(44) A diagram of the kidney transplant recipient cohort selection is
presented in Figure 1.
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Figure 1: Cohort selection.

Ontario Kidney Transplant Recipients
From 1994-2009
n=6396
Exclusion Criteria (n=1442):
- <18 years old (n=290)
- Repeat/previous organ transplant (n=880)
- Simultaneous multi-organ transplant (n=272)

First-time Kidney-only Transplant
Recipients
n=4954

3.4 Population: General Population
We randomly assigned an index date to the entire adult general population in Ontario,
Canada according to the distribution of index dates in recipients. As in the recipients, we
excluded residents who were <18 years old on their assigned index date and looked back
to the beginning of the databases (January 1981 for CORR) to exclude individuals with
chronic kidney disease (CKD; including those who previously received dialysis or a
kidney transplant). Kidney transplant recipients were then matched to the general
population based on age (±1 year), sex, and index date (±6 months) using a 1:4 ratio. No
recipients were lost in the matching process.
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3.5 Primary Outcome
The primary outcome was a composite of death or first major cardiovascular event within
3 years of the index date. A major cardiovascular event was defined as a hospitalization
where the primary diagnosis was myocardial infarction or ischemic stroke, or evidence of
a procedural code for percutaneous coronary intervention or coronary artery bypass graft
surgery. Previous studies in the non-transplant and transplant population have used
similar cardiovascular outcomes.(20,28,38,45) These diagnostic and procedural codes
have also been shown to have good validity when compared with chart review
(Appendix 3). A 3-year follow-up period was chosen in order to compare results to the
U.S. population where Medicare coverage lasts for only 3 years following
transplantation. In addition to this, our estimates of cardiovascular incidence could be
used to inform sample size calculations for future clinical trials.

3.6 Additional Outcomes
Additional outcomes include the components of the primary outcome analyzed separately
[i) death and ii) death-censored major cardiovascular event]. We also examined the
proportion of recipients who received cardiac investigations in the 3 years following
transplantation. To better inform peri-operative outcomes, we assessed the 30-day
cumulative incidence of myocardial infarction and ischemic stroke (where hospital
diagnostic codes were not limited to the primary diagnosis).

3.7 Statistical Analysis
We conducted all analyses with SAS (Statistical Analysis Software) version 9.3 (SAS
Institute Inc., Cary, NC). All patients were followed until the outcome of interest or the
end of the study period (December 31, 2012). We continued to follow all kidney
transplant recipients even if they experienced graft failure (i.e. recipients were followed
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for the outcome of interest even if they returned to chronic dialysis or received a retransplant during the 3-year follow-up period).

Baseline Characteristics
Starting the cohort in 1994 allowed for a minimum of 3 years in the look-back window to
assess for baseline co-morbidities since the CIHI-DAD and OHIP databases were only
available from 1991 onwards. We categorized the study period into 4-year eras and
grouped recipients based on their index dates: 1994-1997, 1998-2001, 2002-2005, and
2006-2009. We reported continuous baseline characteristics as means with standard
distributions for data that was normally distributed or as medians with interquartile range
for data that was skewed. Categorical variables were reported as proportions.
Distributions of baseline characteristics among patients within each era were compared
using the Chi-square test for categorical variables and ANOVA for continuous variables.

Primary Analyses
Having the accrual period end in 2009 allowed for a minimum of 3 years of follow-up to
assess for outcomes since, at the time of analysis, the CIHI-DAD and OHIP databases
were updated until 2012. We assessed changes in the 3-year cumulative incidence of
cardiovascular events over time using the Cochran-Armitage test for trend. We reported
the 95% confidence intervals for the cumulative incidences using the Wilson score
method. We used Cox proportional hazard analyses to examine the association between
transplant era and outcome, adjusting for age, sex, and a history of coronary artery
disease, myocardial infarction, hypertension, and diabetes mellitus at the time of
transplant (referent era was 1994-1997).
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Subgroup Analyses
We repeated the primary analysis in 3 pre-specified subgroups: age at transplantation
(<65 vs. ≥65 years), sex (males vs. females), and donor type (living vs. deceased; the 1%
with missing values were not included in the analysis).

Additional Analyses
We also calculated the incidence rate defined as the rate per 100 person-years of followup. We hypothesized that the incidence rate for the primary outcome would be highest in
the early peri-operative period. To test this hypothesis, for each era, we performed
unadjusted serial Poisson models for the following time periods after transplantation: 0-3
months, 4-12 months, and 13-36 months. Among recipients who experienced an event
within the first 3 years of transplantation, we also assessed the time to the first qualifying
event after transplantation. Given the small number of anticipated events for the 30-day
outcomes of myocardial infarction and ischemic stroke, we reported only the cumulative
incidence for the entire cohort.
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Chapter 4 : Results

4.1 Baseline Characteristics: Kidney Transplant Recipients
Baseline characteristics for 4954 kidney transplant recipients are presented in Table 2.
When recipients were followed for a maximum of 3 years, the total follow-up was 14,096
person-years. Overall, 63% of recipients were males and glomerulonephritis was the
main cause of end-stage renal disease (ESRD) throughout the study period (35% for the
entire cohort). The median time on dialysis prior to transplantation was 2 years
(interquartile range [IQR] 1 to 4) and 41% of recipients received a kidney from a living
donor.
The age and co-morbidity of kidney transplant recipients increased during the
study period. The median age at transplantation increased from 45 years (IQR 35 to 55)
in 1994-1997 to 53 (IQR 42 to 62) in 2006-2009 (p<0.001). Comparing the era 19941997 to 2006-2009, the proportion of recipients aged 65 years and older increased (from
5.7% to 17%; p<0.001), as did the proportion of recipients with pre-transplant coronary
artery disease (from 22% to 37%; p<0.001) and diabetes mellitus (from 21% to 29%;
p<0.001). The proportion of recipients undergoing cardiovascular investigations in the 3
years prior to transplantation increased dramatically across the eras. For example, the
proportion of recipients receiving an echocardiogram increased from 76% in 1994-1997
to 96% in 2006-2009 (p<0.001). Similarly, the proportion of recipients receiving a pretransplant coronary angiogram more than doubled from 9.5% in 1994-1997 to 21% in
2006-2009 (p<0.001).
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Table 2: Baseline characteristics of kidney transplant recipients in Ontario by era.
Total
1994-1997 1998-2001 2002-2005 2006-2009
Characteristic
n=4954
n=1048
n=1110
n=1182
n=1614
Age (years)

p
valuea

49 [38-59]

45 [35-55]

47 [36-57]

51 [41-60]

53 [42-62]

4345 (88)
609 (12)

988 (94)
60 (5.7)

1004 (90)
106 (9.5)

1016 (86)
166 (14)

1337 (83)
277 (17)

<0.001

3120 (63)

664 (63)

681 (61)

759 (64)

1016 (63)

0.55

3385 (68)

800 (76)

784 (71)

796 (67)

1005 (62)

Asian
African-American

321 (6.5)
276 (5.6)

66 (6.3)
42 (4.0)

67 (6.0)
54 (4.9)

66 (5.6)
69 (5.8)

122 (7.6)
111 (6.9)

Indian

268 (5.4)

52 (5.0)

54 (4.9)

65 (5.5)

97 (6.0)

Other
Unknown

222 (4.5)
482 (9.7)

22 (2.1)
66 (6.3)

32 (2.9)
119 (11)

51 (4.3)
135 (11)

117 (7.2)
162 (10)

1088 (22)
990 (20)

235 (22)
207 (20)

219 (20)
219 (20)

264 (22)
240 (20)

370 (23)
324 (20)

0.80

933 (19)
4367 (88)

190 (18)
920 (88)

231 (21)
968 (87)

230 (20)
1051 (89)

282 (17)
1428 (88)

0.15

Glomerulonephritis
Diabetes mellitus

1733 (35)
900 (18)

416 (40)
153 (15)

418 (38)
196 (18)

391 (33)
220 (19)

508 (31)
331 (21)

Cystic

656 (13)

120 (11)

148 (13)

170 (14)

218 (14)

Vascular
Other

518 (10)
759 (15)

92 (8.8)
158 (15)

97 (8.7)
167 (15)

141 (12)
201 (17)

188 (12)
233 (14)

Unknown
Donor type

388 (7.8)

109 (10)

84 (7.6)

59 (5.0)

136 (8.4)

Deceased

2839 (57)

667 (64)

605 (55)

643 (54)

924 (57)

Living
Unknown

2048 (41)
67 (1.4)

348 (33)
33 (3.1)

492 (44)
13 (1.2)

531 (45)
8 (0.7)

677 (42)
13 (0.8)

446 (9.0)
2978 (60)

66 (6.3)
544 (52)

107 (9.6)
673 (61)

101 (8.5)
764 (65)

172 (11)
997 (62)

<0.001

1530 (31)
2 [1-4]

438 (42)
2 [1-4]

330 (30)
2 [1-4]

317 (27)
3 [1-5]

445 (28)
3 [1-6]

<0.001

<65
≥65
Male
Race
Caucasian

<0.001

Income quintileb
Lowest
Middle
Highest
Urban residencec
Cause of ESRD

<0.001

<0.001

Pre-transplant dialysis modality
Pre-emptived
Hemodialysis
Peritoneal
Dialysis vintage (years)
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Delayed graft functione
Primary non-functionf

1331 (27)
389 (7.9)

283 (27)
88 (8.4)

292 (26)
71 (6.4)

296 (25)
90 (7.6)

460 (29)
140 (8.7)

0.22
0.15

Coronary artery disease
Hypertension

1527 (31)
3670 (74)

235 (22)
820 (78)

312 (28)
859 (77)

410 (35)
871 (74)

597 (37)
1120 (69)

<0.001
<0.001

Diabetes mellitus

1275 (26)

224 (21)

267 (24)

323 (27)

461 (29)

<0.001

Myocardial infarction
PCI

99 (2.0)
115 (2.3)

13 (1.2)
9 (0.9)

17 (1.5)
15 (1.4)

32 (2.7)
30 (2.5)

37 (2.3)
61 (3.8)

0.045
<0.001

CABG surgery
Heart failure

119 (2.4)
692 (14)

11 (1.0)
171 (16)

21 (1.9)
160 (14)

38 (3.2)
167 (14)

49 (3.0)
194 (12)

0.001
<0.001

67 (1.4)

13 (1.2)

21 (1.9)

14 (1.2)

19 (1.2)

0.37

483 (9.7)

83 (7.9)

103 (9.3)

117 (9.9)

180 (11)

0.048

Echocardiography
Stress test

4388 (89)
3567 (72)

801 (76)
518 (49)

956 (86)
718 (65)

1081 (91)
947 (80)

1550 (96)
1384 (86)

<0.001
<0.001

Coronary angiogram

831 (17)

100 (9.5)

164 (15)

235 (20)

332 (21)

<0.001

Carotid ultrasound

885 (18)

146 (14)

180 (16)

256 (22)

303 (19)

<0.001

Co-morbiditiesg

Stroke/TIA
Cardiovascular investigations
Holter monitor

g

Data presented as number (percentage) or median [interquartile range].
a
Chi-square test for categorical variables and ANOVA for continuous variables (e.g. age, dialysis vintage).
b
Income was categorized according to fifths of average neighborhood income, with the first quintile calculated
as the lowest income and the fifth quintile as the highest income. Missing values (0.3%) were categorized into
the middle quintile.
c
Urban location indicates a population >10,000.
d
Recipients identified as pre-emptive in the Canadian Organ Replacement Register were assessed for the
presence of dialysis codes and re-classified as hemodialysis (n=26) or peritoneal dialysis (n=35).
e
Delayed graft function was defined as a dialysis code within the first 7 days of transplantation.
f
Primary non-function was defined as 3 dialysis codes on 3 separate days with at least 1 dialysis
code appearing in the first 7 days of transplantation, between day 8 and 30 of transplantation, and
between day 31 and 60 of transplantation.
g
Assessed by the presence of a diagnostic or procedural code in the 3 years prior to the transplant except for
hypertension and diabetes mellitus which are defined as the presence of either 2 OHIP codes or 1
hospitalization with a diagnosis of hypertension or diabetes mellitus, respectively, in the 3 years prior to the
transplant (an algorithm previously validated for hypertension and diabetes mellitus).(46,47)
Abbreviations: CABG, coronary artery bypass graft; ESRD, end-stage renal disease; OHIP, Ontario Health
Insurance Plan; PCI, percutaneous coronary intervention; TIA, transient ischemic attack.
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4.2 Baseline Characteristics: General Population
The baseline characteristics of the matched general population (n=19,816) are presented
in Table 3. The total follow-up time for the general population was 58,673 person-years.
As expected, kidney transplant recipients had more co-morbidities than the general
population, including coronary artery disease (31% vs. 4.9%), hypertension (74% vs.
20%), heart failure (14% vs. 1.1%), and diabetes mellitus (26% vs. 8.1%).
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Table 3: Baseline characteristics of the matched general population in Ontario by era.
Total
1994-1997 1998-2001 2002-2005 2006-2009
Characteristic
n=19,816
n=4192
n=4440
n=4728
n=6456

p
valuea

Age (years)

49 [38-59]

45 [35-55]

47 [36-57]

51 [41-60]

53 [42-62]

<0.001

Male
Income quintileb

12,480 (63)

2656 (63)

2724 (61)

3036 (64)

4064 (63)

0.039

Lowest

3955 (20)

859 (20)

890 (20)

929 (20)

1277 (20)

Middle
Highest

3846 (19)
4139 (21)

837 (20)
835 (20)

839 (19)
920 (21)

899 (19)
1001 (21)

1271 (20)
1383 (21)

0.82

17,444 (88)

3699 (88)

3922 (88)

4128 (87)

5695 (88)

0.41

Coronary artery disease

980 (4.9)

180 (4.3)

178 (4.0)

258 (5.5)

364 (5.6)

<0.001

Hypertension
Diabetes mellitus

3981 (20)
1608 (8.1)

611 (15)
216 (5.2)

750 (17)
268 (6.0)

1038 (22)
407 (8.6)

1582 (25)
717 (11)

<0.001
<0.001

Myocardial infarction

118 (0.6)

21 (0.5)

29 (0.7)

26 (0.5)

42 (0.7)

0.71

PCI
CABG surgery

87 (0.4)
72 (0.4)

7 (0.2)
12 (0.3)

10 (0.2)
16 (0.4)

24 (0.5)
17 (0.4)

46 (0.7)
27 (0.4)

<0.001
0.75

Heart failure
Stroke/TIA

225 (1.1)
57 (0.3)

45 (1.1)
14 (0.3)

52 (1.2)
9 (0.2)

48 (1.0)
15 (0.3)

80 (1.2)
19 (0.3)

0.70
0.66

Holter monitor
Echocardiography

610 (3.1)
1542 (7.8)

106 (2.5)
208 (5.0)

96 (2.2)
256 (5.8)

149 (3.2)
376 (8.0)

259 (4.0)
702 (11)

<0.001
<0.001

Stress test

1675 (8.5)

246 (5.9)

294 (6.6)

438 (9.3)

697 (11)

<0.001

Coronary angiogram
Carotid ultrasound

264 (1.3)
426 (2.1)

37 (0.9)
67 (1.6)

42 (0.9)
68 (1.5)

68 (1.4)
117 (2.5)

117 (1.8)
174 (2.7)

<0.001
<0.001

Urban residencec
Co-morbiditiesd

Cardiovascular investigationsd

Data presented as number (percentage) or median [interquartile range].
a
Chi-square test for categorical variables and ANOVA for continuous variables (e.g. age).
b
Income was categorized according to fifths of average neighborhood income, with the first quintile calculated
as the lowest income and the fifth quintile as the highest income.
c
Urban location indicates a population >10,000.
d
Assessed by the presence of a diagnostic or procedural code in the 3 years prior to the transplant except for
hypertension and diabetes mellitus which are defined as the presence of either 2 OHIP codes or 1
hospitalization with a diagnosis of hypertension or diabetes mellitus, respectively, in the 3 years prior to the
transplant (an algorithm previously validated for hypertension and diabetes mellitus).(46,47)
Abbreviations: CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; TIA, transient
ischemic attack.
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4.3 Primary Outcome: Death or Major Cardiovascular Event
Kidney Transplant Recipients
The 3-year cumulative incidence and incidence rate of death or first major cardiovascular
event for the entire cohort and for each era are presented in Table 4. There were a total of
445 composite outcome events (263 deaths and 182 major cardiovascular events, of
which, 81 were myocardial infarctions) within the first 3 years following kidney
transplantation (9.0%; 95% confidence interval [CI] 8.2% to 9.8%; 3.2 events per 100
person-years). The 3-year cumulative incidence of death or major cardiovascular event
remained stable from 8.4% in 1994-1997 to 9.0% in 2006-2009 (p=0.41). When we
adjusted for age, sex, and a history of coronary artery disease, myocardial infarction,
hypertension, and diabetes mellitus, the risk of death or major cardiovascular event
steadily declined across the eras (2006-2009 adjusted hazard ratio, aHR, 0.70; 95% CI
0.54 to 0.92; p=0.009; referent 1994-1997).
As expected, the highest incidence rate for each era was in the first 0-3 months
after transplantation and steadily declined thereafter (Table 5). Overall, the incidence rate
was 7.96 events per 100 person-years for the first 0-3 months following transplantation,
2.18 in the 4-12 months following transplantation, and 1.75 in the 13-36 months
following transplantation. Among recipients who experienced an event, the time from
transplantation to death or major cardiovascular event remained stable throughout the
eras with a median time to event of 0.7 years (IQR 0.2 to 2.0) in 1994-1997 and 1.3 years
(IQR 0.3 to 2.2) in 2006-2009.
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Table 4: Death or major cardiovascular eventa among kidney transplant recipients within 3 years following
transplantation.
Total
1994-1997 1998-2001
2002-2005
2006-2009
p
n=4954
n=1048
n=1110
n=1182
n=1614
valueb
Number (%) of events
445 (9.0)
88 (8.4)
94 (8.5)
117 (9.9)
146 (9.0)
0.41
Number of events
3.2
2.9
3.0
3.5
3.2
per 100 person-years
Median time (years) to event
1.2
0.7
1.3
1.4
1.3
[IQR]
[0.3-2.1]
[0.2-2.0]
[0.3-2.0]
[0.5-2.2]
[0.3-2.2]
c
Number (%) of types of events
Death
263 (5.3)
51 (4.9)
49 (4.4)
79 (6.7)
84 (5.2)
0.33
Myocardial infarction
81 (1.6)
18 (1.7)
21 (1.9)
17 (1.4)
25 (1.5)
0.56
d
PCI or CABG surgery
68 (1.4)
13 (1.2)
16 (1.4)
10 (0.8)
29 (1.8)
0.34
Ischemic stroke
33 (0.7)
6 (0.6)
8 (0.7)
11 (0.9)
8 (0.5)
0.83
1.00
1.01
1.18
1.08
Unadjusted hazard ratio (95% CI)
0.43
(Referent) (0.75-1.35) (0.90-1.56) (0.83-1.40)
1.00
0.89
0.83
0.70
Adjusted hazard ratioe (95% CI)
0.009
(Referent) (0.66-1.19) (0.63-1.10) (0.54-0.92)
a
Major cardiovascular event was defined as either myocardial infarction, PCI, CABG surgery, or ischemic
stroke.
b
Cochran-Armitage test for trend except for hazard ratios for which Chi square was used..
c
Only the first event is considered in this analysis.
d
Due to the low number of events and for privacy reasons, the outcomes for PCI and CABG are reported in
combination in this table.
e
Adjusted for age, sex, and a history of coronary artery disease, myocardial infarction, hypertension, and diabetes
mellitus at the time of transplantation.
Abbreviations: CABG, coronary artery bypass graft; CI, confidence interval; IQR, interquartile range; PCI,
percutaneous coronary intervention.
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Table 5: Incidence rate of death or major cardiovascular eventa during 3 follow-up periods after
kidney transplantation for recipients in each era.
Era
Incidence rate per 100 person-years (95% confidence interval)b
0-3 months
4-12 months
13-36 months
1994-1997 (n=1048)
8.60 (5.66 to 13.06) 2.67 (1.83 to 3.89)
1.32 (0.96 to 1.80)
1998-2001 (n=1110)
7.39 (4.77 to 11.46) 1.76 (1.12 to 2.75)
1.74 (1.34 to 2.27)
2002-2005 (n=1182)
6.59 (4.20 to 10.33) 2.43 (1.68 to 3.52)
2.10 (1.66 to 2.65)
2006-2009 (n=1614)
8.67 (6.20 to 12.14) 1.79 (1.23 to 2.59)
1.84 (1.48 to 2.27)
Overall
7.96 (6.53 to 9.70) 2.18 (1.80 to 2.63)
1.75 (1.55 to 1.99)
a
Major cardiovascular event was defined as either myocardial infarction, PCI, CABG surgery, or
ischemic stroke.
b
Unadjusted Poisson model.
Abbreviations: CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention.
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Subgroup Analysis
There was no difference in the primary outcome across the eras within age, sex, or donor
type strata (Figure 2, Figure 3, and Figure 4, respectively). Throughout the study period,
as expected a higher proportion of events were observed in the older population (19% for
recipients ≥65 years old at the time of transplant vs. 7.6% for recipients <65 years;
p<0.001), in males vs. females (9.6% vs. 7.9%; p=0.04), and in recipients of deceased
donor kidneys vs. living donor kidneys (11% vs. 5.5%; p<0.001).

Figure 2: 3-year cumulative incidence of death or major cardiovascular event from 1994
to 2009 stratified by age.
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Figure 3: 3-year cumulative incidence of death or major cardiovascular event from 1994
to 2009 stratified by sex.
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Figure 4: 3-year cumulative incidence of death or major cardiovascular event from 1994
to 2009 stratified by donor type.
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Comparison to the General Population
A comparison of the primary outcome in kidney transplant recipients to the general
population (matched on age, sex, and index date) is presented in Figure 5. Overall, the 3year cumulative incidence and rate of death or first major cardiovascular event was lower
in the general population (2.6%; 95% CI 2.4% to 2.9%; 0.89 events per 100 person-years;
p<0.001) compared to recipients, with a trend towards increasing incidence over time
(2.0% in 1994-1997 to 2.8% in 2006-2009; p=0.008).
Figure 5: 3-year cumulative incidence of death or major cardiovascular event from 1994
to 2009 in matched kidney transplant recipients and general population. The general
population cohort excluded individuals with chronic kidney disease, a history of dialysis
or previous kidney transplantation. Kidney transplant recipients were matched 1:4 to
members of the general population based on age, sex, and index date.
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4.4 Additional Outcome: Death
The components of the primary outcome were examined separately. There were 306
deaths within 3 years following transplantation (6.2%; 95% CI 5.5% to 6.9%; 2.1 events
per 100 person-years) with no difference across the eras (5.6% in 1994-1997 vs. 6.3% in
2006-2009; p=0.17) (Table 6). The 3-year cumulative incidence and rate of death was
lower in the general population (1.4%; 95% CI 1.3% to 1.6%; 0.5 events per 100 personyears; p<0.001) compared to recipients, with a trend towards increasing incidence over
time (p=0.017) (Figure 6).

Table 6: Secondary outcomes of 3-year cumulative incidence of death, cardiovascular events, and
cardiovascular investigations among kidney transplant recipients.
Number (%) of events

Total
n=4954
306 (6.2)

1994-1997
n=1048
59 (5.6)

1998-2001
n=1110
56 (5.0)

2002-2005
n=1182
89 (7.5)

2006-2009
n=1614
102 (6.3)

p
valuea
0.17

Death
Cardiovascular events
(censored for death)b
Major cardiovascular eventc
182 (3.7)
37 (3.5)
45 (4.1)
38 (3.2)
62 (3.8)
0.92
Myocardial infarction
81 (1.6)
18 (1.7)
21 (1.9)
17 (1.4)
25 (1.5)
0.56
PCI
67 (1.4)
12 (1.1)
15 (1.4)
11 (0.9)
29 (1.8)
0.21
Ischemic stroke
36 (0.7)
8 (0.8)
8 (0.7)
11 (0.9)
9 (0.6)
0.61
Cardiovascular investigations
Holter monitor
395 (8.0)
64 (6.1)
82 (7.4)
80 (6.8)
169 (11)
<0.001
Echocardiography
1898 (38)
305 (29)
359 (32)
450 (38)
784 (49)
<0.001
Stress test
1133 (23)
204 (19)
222 (20)
269 (23)
438 (27)
<0.001
Coronary angiogram
81 (1.6)
10 (1.0)
17 (1.5)
16 (1.4)
38 (2.4)
0.008
Carotid ultrasound
366 (7.4)
74 (7.1)
84 (7.6)
73 (6.2)
135 (8.4)
0.32
a
Cochran-Armitage test for trend.
b
Due to the low number of events and for privacy reasons, the outcomes for CABG are not reported in this
table. The total number of events was 42 (0.8%) with no significant change over time (p=0.63).
c
Major cardiovascular event was defined as either myocardial infarction, PCI, CABG surgery, or ischemic
stroke.
Abbreviations: CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention.
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Figure 6: 3-year cumulative incidence of death from 1994 to 2009 in matched kidney
transplant recipients and general population. The general population cohort excluded
individuals with chronic kidney disease, a history of dialysis or previous kidney
transplantation. Kidney transplant recipients were matched 1:4 to members of the general
population based on age, sex, and index date.
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4.5 Additional Outcome: Death-Censored Major
Cardiovascular Events
In kidney transplant recipients, there was no significant change in the 3-year cumulative
incidence of death-censored major cardiovascular events (182 events; 3.7%; 95% CI
3.2% to 4.2%; 1.2 events per 100 person-years) across the eras (3.5% in 1994-1997 vs.
3.8% in 2006-2009; p=0.92) (Table 6). The 3-year incidence of death-censored major
cardiovascular event was lower in the general population (1.3%; 95% CI 1.2% to 1.5%;
0.4 events per 100 person-years; p<0.001) compared to recipients, with no significant
change over time in either group (p=0.14) (Figure 7).
In kidney transplant recipients, the 3-year cumulative incidence of myocardial
infarction was 1.7% in 1994-1997 compared to 1.5% in 2006-2009 (p=0.56) (Table 6).
When examined separately, the 3-year cumulative incidences of percutaneous coronary
intervention, coronary artery bypass graft surgery, and ischemic stroke also remained
stable throughout the eras.
There was a trend towards more cardiac investigations (Holter monitor,
echocardiography, stress testing, coronary angiogram) in the 3-years following kidney
transplantation in the more recent eras (Table 6). The use of carotid ultrasounds remained
stable throughout the eras.
Lastly, in the post-operative transplant period, the 30-day cumulative incidence of
myocardial infarction was 1.5% while the 30-day cumulative incidence of ischemic
stroke was 0.3%.

31

Figure 7: 3-year cumulative incidence of death-censored major cardiovascular event
from 1994 to 2009 in matched kidney transplant recipients and general population. The
general population cohort excluded individuals with chronic kidney disease, a history of
dialysis or previous kidney transplantation. Kidney transplant recipients were matched
1:4 to members of the general population based on age, sex, and index date.
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Chapter 5 : Discussion

5.1 Summary of Key Findings
In this study, we found that the 3-year cumulative incidence of death or major
cardiovascular event in kidney transplant recipients was 9.0% and, reassuringly, has
remained stable over time despite increasing recipient age and co-morbidities in the more
recent eras. When we adjusted for age, sex, and baseline co-morbidities, there was a trend
towards a decreasing risk of death or major cardiovascular event across the eras.
The incidence rate was highest in the first 3 months after transplantation and steadily
declined thereafter. There was no difference in the primary outcome when the results
were stratified by age, sex, and donor type. Compared to the general population, kidney
transplant recipients have a higher incidence of death or major cardiovascular event.
Similar results were seen when the components of the primary outcome were
examined separately. The 3-year cumulative incidence of death in kidney transplant
recipients was 6.2% and for death-censored major cardiovascular event was 3.7%, with
no significant change over time for either outcome. The 3-year cumulative incidence of
myocardial infarction was 1.6% and for ischemic stroke was 0.7% with no significant
change over time.

5.2 Comparison of Results to Previous Research
Similar to an Australian study, we found a trend towards a greater proportion of older
recipients with more co-morbidities in recent years.(8) This trend may be due to the
increasing rate of treated end-stage renal disease (ESRD) among the elderly (over a third
are now >70 years old).(48,49) While younger recipients do have higher patient and graft
survival rates compared to older recipients,(49) studies have shown that older patients
still have a survival benefit with kidney transplantation compared to remaining on
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dialysis and that death-censored graft survival is similar to younger recipients.(1,50–53)
This raises ethical dilemmas in the allocation of scarce resources and a growing number
of patients on the transplant waiting list.(54,55) Of note, the United States (U.S.) recently
implemented a revised deceased donor allocation policy in December 2014 which
prioritizes kidney transplant candidates with the highest expected post-transplant survival
(a metric based on age, diabetes mellitus, dialysis time, and prior transplant status) for the
highest quality organs.(56) Despite the favourable outcomes with transplantation for
older patients on the waiting list, there are concerns regarding this population’s higher
risk of death with a functioning graft as well as post-transplant complications including
cardiovascular events.(54) Reassuringly, we found that the 3-year cumulative incidence
of death or major cardiovascular event in this older age group has remained stable.
The overall 3-year cumulative incidence of death or major cardiovascular event
was 9.0% in our cohort while the 3-year cumulative incidence of myocardial infarction
and ischemic stroke were 1.6% and 0.7%, respectively. These estimates are lower than
the 11% and 3.5% 3-year cumulative incidence of myocardial infarction and ischemic
stroke reported in Lentine’s et al. retrospective studies of Medicare-insured kidney
transplant recipients followed through the United States Renal Data System
(USRDS).(7,57) The higher cumulative incidence of myocardial infarction in the U.S.
study compared to our Canadian study may be due to differences in baseline
characteristics between the two cohorts and/or how myocardial infarction events were
captured. The U.S. cohort had a higher proportion of older recipients (22% of U.S.
recipients were ≥60 years compared to 12% of our recipients were ≥65 years) and a
higher proportion of recipients for whom diabetes mellitus was the primary cause of
ESRD (25% vs. 18%). The U.S. cohort also had a higher proportion of recipients with
concurrent co-morbidities at the time of transplant. For example, 45% of U.S. recipients
had diabetes mellitus vs. 26% of our recipients and 8% of U.S. recipients had a history of
myocardial infarction pre-transplant compared to 2% of our cohort. However, baseline
co-morbidities may be under-represented in our cohort given that they only reflect
recorded diagnostic and procedural codes present in the 3 years prior to transplantation.
In addition, we restricted our events to hospitalizations within 3 years of transplantation
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where the most responsible diagnosis was myocardial infarction whereas the U.S. study
included any Medicare billing claims within 3 years of transplantation with a diagnosis of
myocardial infarction or death due to myocardial infarction. A previous validation study
has shown that a most responsible diagnosis of acute myocardial infarction has a
specificity, sensitivity, and positive predictive value of 93%, 89%, and 89%, respectively.
Thus, myocardial infarctions or strokes occurring in the immediate peri-operative period
are unlikely to be captured in our primary analysis, as the most responsible diagnosis
related to the admission would likely be the kidney transplantation rather than
complications arising post-operatively.
Regarding peri-operative events, in our secondary analysis we did not limit the
hospital diagnostic code to most responsible or primary diagnosis and found that the 30day cumulative incidence of myocardial infarction was 1.5% while the 30-day cumulative
incidence of ischemic stroke was 0.3%. This is similar to a previous retrospective singlecenter study by Humar et al. who found that in a cohort of 2694 kidney transplant
recipients the 30-day incidence of myocardial infarction was 1.6%.(58) We did confirm
that the highest incidence rate of death or major cardiovascular event occurred during the
first 0-3 months after transplantation (7.96 events per 100 person-years in the first 0-3
months vs. 2.18 events per 100 person-years in the 4-12 months vs. 1.75 events per 100
person-years in the 12-36 months).
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5.3 Further Discussion of Results
There are many possible reasons for the stable rate of observed events in our cohort
despite the changing baseline characteristics of our recipients. One reason may be the
increase in living donor kidneys over time for which these recipients, in our study, were
found to have a lower risk of death or cardiovascular event compared to deceased donor
kidney recipients (overall, 5.5% for living donor kidneys vs. 11% for deceased donor
kidneys). Another possible reason may be the careful assessment and selection process of
kidney transplant candidates. In recent years, we noted a dramatic increase in the
proportion of recipients who received cardiac investigations in the 3 years prior to their
transplant, likely as part of their transplant assessment and/or cardiac surveillance while
on the transplant waiting list. A survey of transplant programs in the U.S. showed wide
variability in the use of invasive and non-invasive cardiac investigations used as part of
the screening and surveillance of potential kidney transplant candidates.(59) Among
Medicare-insured transplant recipients in the U.S. between 1991 and 2004, 46% (65% of
high-risk and 20% of lower-risk patients) underwent cardiac evaluation testing before
transplantation.(60) Kidney transplant recipients who were younger, female, AfricanAmerican, or had a shorter duration on dialysis were less likely to undergo pre-transplant
cardiac evaluation with non-invasive stress testing and angiography.
Although there are recommendations on the cardiac evaluation and surveillance of
potential transplant recipients, these tests have been inconsistent in predicting or
mitigating post-transplant cardiovascular mortality or morbidity.(6) A Cochrane review
of cardiac testing for coronary artery disease in kidney transplant candidates suggested
that dobutamine stress echocardiography is the screening investigation of choice but
recognized the limitation of cardiac testing in predicting cardiac event-free survival after
transplantation.(61) Similarly, a Canadian prospective study from British Columbia of
604 patients on the kidney transplant waiting list between 1998 and 2001 found that the
use of non-invasive cardiac investigation prior to transplant was not predictive of the time
to a cardiovascular event post-transplant.(62) In our study, we cannot attribute the
stability of post-transplantation cardiovascular events to the increase in cardiac testing
pre-transplantation. Currently there is no evidence from randomized trials demonstrating
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that pre-operative cardiac screening of asymptomatic patients reduces risk of major
cardiovascular events or improves survival after transplantation or other forms of
surgery.(6)
Finally, progressive improvements in the diagnosis and medical management of
cardiovascular events in patients with chronic kidney disease (CKD) may explain our
findings.(29,63–65) As above, there is a lack of randomized controlled trials proving
efficacy of pharmacological interventions in the reduction of cardiovascular events in
patients with renal disease as these patients are often excluded from the trials.(66) Thus,
physicians often extrapolate findings from the general population to the CKD population
despite their unique cardiac risk factors and pathophysiology.(29) Unfortunately, we did
not have complete information on cardio-protective medications, such as beta-blockers or
statins, in our data sources given that a significant proportion of recipients are covered by
private drug plans.
Despite the stable cumulative incidence of cardiovascular events over time,
kidney transplant recipients had a 6.4% higher risk of death or major cardiovascular event
compared to the general population. As previously stated, this is likely due to the
combination of traditional cardiovascular risk factors and renal-specific cardiovascular
risk factors that are highly prevalent in this unique patient population.(21,23) Traditional
cardiovascular risk factors include hypertension, diabetes mellitus, hyperlipidemia,
smoking, older age, and physical inactivity. Renal-specific factors include decreased
renal function (compared to the general population), immunosuppressive medications,
episodes of rejection and graft loss, and donor type (living vs. deceased
donors).(20,23,24) In our subgroup analyses, the risk of death or major cardiovascular
event was higher in kidney transplant recipients who were older and had received kidneys
from deceased donors.
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5.4 Study Strengths
Our study has a number of strengths. To our knowledge, this is the first study assessing
secular trends of death and major cardiovascular events in kidney transplant recipients.
Our study was made possible because of Ontario’s universal healthcare benefits, with the
collection of all healthcare encounters for all citizens, including almost 5000 transplant
recipients followed in this study. This minimizes concerns about selection and
information biases. We relied on diagnostic and procedural codes for our outcomes with
proven validity compared to chart review.

5.5 Study Limitations
There are some limitations to our study. We did not have accurate and complete data to
compare our results to a population of patients receiving chronic dialysis while on the
transplant waiting list. Cause of death could not be accurately obtained in our data
sources. We relied on administrative data collected for non-research purposes, which
limit the type of data available for applying inclusion/exclusion criteria as well as for
outcome measurements. Claims are surrogate measures for diagnoses and procedures, but
have been shown to have high sensitivity and specificity compared with chart review and
registry data in the general Ontario population (Appendix 3). High sensitivity of
Medicare billing claims for cardiovascular diagnoses and procedures in the kidney
transplant population has also been demonstrated in the U.S.(67) Residual confounding,
inherent to any observational study, may affect the association between year of transplant
and outcomes. Historical information such as smoking, cardio-protective medications,
immunosuppression use, physical exam values such as blood pressure measurements,
laboratory data such as serum creatinine or cardiac troponin, and investigational findings
such as echocardiography results were unavailable or incomplete from our data sources.
Lastly, secular changes in coding practices or outcome definitions may have influenced
our results although most codes have remained stable over time.
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5.6 Conclusion
We report a stable cumulative incidence over time of post-transplant death or major
cardiovascular event in kidney transplant recipients despite increasing recipient age and
co-morbidities. Our results are reassuring for transplant programs and may reflect
advances in the prevention and treatment of cardiovascular disease in kidney transplant
recipients.
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transplantation. We will compare these incidences to the general population.
1. CORR (Jan 1981 – Dec 2012)
2. RPDB (Jan 1991 – Dec 2012)
3. CIHI-DAD (Jan 1991 – Dec 2012)
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Diagnosis Type (dxtype)
List of Datasets Used
All (alldx) (for baseline characteristics)
Most responsible diagnosis (M) (for cardiovascular outcomes)
Study period
Prior to 2002 fiscal year à INCLUDE ICD-9 CODES in Appendix A, B, E
From 2002 fiscal year and onwards à INCLUDE ICD-10 CODES in Appendix
A, B, E
Include suspected/questionable diagnoses?
No

49

Reference date
Do include index date in look-forward period (start at index)
Include abandoned procedures?
No
4. OHIP (July 1991 – Dec 2012)
Claim Type
Non-lab claims
Code Types
Feecodes à INCLUDE FEECODES in Appendix A, B, E
Diagnosis codes à INCLUDE DIAGNOSIS CODES in Appendix A, B, E

Design: Retrospective Cohort Study
Defining the Cohort
Index Event
Inclusion
Criteria
(Table 1a,
Table 1b,
Table 1c)

Year of first kidney-only transplantation (from a deceased or living donor) during the study
period (1994 to 2009) using CORR as the data source for kidney transplant recipients.
1) Cohort A: Kidney transplant recipients (KTx)
All incident kidney-only transplant recipients in Ontario from January 1, 1994 to December
31, 2009 with a valid IKN.
CORR Dataset: RECIPIENT_TREATMENT
- Variable: TREATMENT_CODE = 171 (Acute Care Hospital, Transplantation, Total Care)
- Variable: TREATMENT_DATE (date of transplant)
- Variable: TRANSPLANTED_ORGAN_TYPE_CODE[1-3]
CORR: TRANSPLANTED_ORGAN_TYPE_CODE[1-3]
Kidneys/Dialysis (includes enbloc transplants)
Kidney – Left
Kidney – Right
Kidney – One (from conversion)
Kidney – Two (from conversion)

Code
10
11
12
18
19

2) Cohort B: General population (GP)
Restrict to those in RPDB. Randomly assign an index date (from January 1, 1994 to
December 31, 2009) to all based on the distribution of the index dates in the kidney
th
th
th
transplant recipients above (minimum, maximum, 25 , 50 , 75 percentiles).
Exclusions
(In order)
(Table 1)

Data cleaning steps (both cohorts)
1. Exclude if invalid or missing IKN, date of birth, or sex
2. Death before the index date in RPDB
3. Exclude non-Ontario residents (use the “%getdemo” macro, the “prcddablk” variable,
exclude recipients whose province code, pr, is not “35”)
Further exclusions (4 to 5a-c are both cohorts)
4. Exclude if age <18 at index date (RPDB)
5. Look back from the index date to 1981 for CORR or 1991 for CIHI-DAD/OHIP for the
following:
a. Exclude if repeat/previous kidney transplant or history of non-kidney transplant.
CORR Dataset: RECIPIENT_TREATMENT
- Variable: TREATMENT_CODE = 171 or 181
For Cohort A (KTx), only include first transplant event, not re-transplants; i.e. first 171 for a
given patient. Index transplant should be the first transplant only.
b. Exclude if CORR reports graft number ≥2
CORR Dataset: TRANSPLANTED_KIDNEY
- Variable: GRAFT_NUM ≥2
For Cohort A (KTx), should be 1 for all recipients.
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c. Exclude if evidence of CIHI-DAD or OHIP codes for kidney transplant (Appendix A) from
beginning of available databases to -60 days before index date
Cohort A (KTx) only
6. Exclude if simultaneous multi-organ transplant recipient including kidney-pancreas
CORR Dataset: RECIPIENT_TREATMENT
- Variable: TRANSPLANTED_ORGAN_TYPE_CODE[1-3] as above (in inclusion #1)
Cohort B (GP) only
6. Look back from the index date to 1981 for CORR or 1991 for CIHI-DAD/OHIP for the
following:
a) Exclude if evidence of chronic dialysis in CORR.
CORR Dataset: RECIPIENT_TREATMENT (Dialysis codes in Appendix D)
b) Exclude if evidence of CIHI-DAD or OHIP codes for dialysis (Appendix A) before the
index date
7. Exclude if evidence of CIHI-DAD code for CKD before the index date (look back to 1991)
(CKD codes in Appendix D).
Matching
Match up to 4 controls (Cohort B [GP]) to each recipient (Cohort A [KTx]) on the following
characteristics:
i) Index date (± 6 months; when possible, ensure control has the same index year as the
recipient)
ii) Age at index date (± 1 year)
iii) Sex
Size of Cohort Based on previous analyses, we anticipate that between 1994 to 2009, there will be
approximately 5000 incident kidney-only transplant recipients (from living or deceased
donors) eligible for inclusion into the study cohort.

Time Frame Definitions
Accrual Window

Max Follow-up Date

Observation Window

Look-back Window

(in which to look for outcomes)
Cohort Entry Date

Accrual Start/End Dates
Max Follow-up Date
When Does Observation
Window Terminate?

Look-back Window(s)

Start: January 1, 1994
End: December 31, 2009
December 31, 2012
Termination occurs (whichever comes first):
1. Observed outcome/event (see Outcome Definitions section)
2. End of follow-up (either pre-defined follow-up period of 30 days, 3 years, 5
years, or 10 years based on outcome) or end of study period (Dec 31, 2012)
3. Death
3 years prior to index date for co-morbid conditions (earliest potential date is
January 1, 1991)
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Variable Definitions
Main Exposure Year of kidney-only transplantation from either a living or deceased donor.
or Risk Factor CORR Dataset: RECIPIENT_TREATMENT
- Variable: TREATMENT_DATE (year of transplant)
Baseline
Note: There will be a separate cohort for each accrual era (era that patient is put into
Characteristics depends on when the patient has their transplant: 1994-1997, 1998-2001, 2002-2005, 2006(Table 2a,
2009). Therefore, there will be 4 consecutive cohorts for the primary outcome.
Table 2b,
Table 2c)
Observed at the time of the index date – Demographics (CORR, RPDB) (Table 2):
(Appendix B)
Record mean (with standard deviation), median (with interquartile range), minimum,
maximum, and/or categorical number N(%) for the following variables as indicated for all 3
cohorts except where indicated:
1. Age at index date: Years, mean±SD, median (IQR), minimum, maximum; Categories: ≤44
years, 45-64 years, ≥65 years, N(%) (RPDB)
2. Sex: Female, Male, N(%) (RPDB)
3. Race (Cohort A [KTx] only): Categories: Caucasian (White), Asian, Black, Indian
Subcontinent, Other, Unknown/Missing, N(%)
CORR Dataset: RECIPIENT
- Variable: RACIAL_ORIGIN_CODE
Look back to the beginning of CORR (1981) to find race.
CORR:
Examples
Codes
RACIAL_ORIGIN_CODE
Caucasian (White)
French Canadians, European, Australian, Russian
01
ancestry
Asian
Chinese, Japanese, Vietnamese, Korean,
02
Taiwanese
Black
African, Jamaican, Haitian, Somali
03
Indian Subcontinent
Indian, Pakistani, Bangladesh
05
Other
Filipino
08
Aboriginal (North American Indian, Metis, Inuit)
09
Middle Eastern/Arabian (Saudi Arabian, Iranian,
10
Iraqi, Jordanian, Syrian, Armenian, Algerian)
Latin American (Caribbean, South American,
11
Cuban)
Other/Multiracial
99
Unknown
Unknown
98
4. Income quintile: Quintile 1-5, Missing, N(%) (PCCF, use PSTLYEAR data and index year)
5. Rural location: Rural, Urban, Missing, N(%)
Observed at the time of the index date – Kidney-related factors (CORR) (Table 2):
Record categorical number (%) for the following variables (Cohort A [KTx] only):
1. Index date: N(%); Categories/Eras: 1994-1997, 1998-2001, 2002-2005, 2006-2009
CORR Dataset: RECIPIENT_TREATMENT
- Variable: TREATMENT_CODE = 171
- Variable: TREATMENT_DATE
- Variable: TRANSPLANTED_ORGAN_TYPE_CODE[1-3] (see table in Inclusion Criteria)
2. Primary cause of end-stage renal disease: Glomerulonephritis/Autoimmune, Cystic Kidney
Disease, Diabetes, Renal Vascular Disease, Other, Unknown/Missing, N(%) (Appendix C)
CORR Dataset: RECIPIENT_TREATMENT
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- Variable: PRIMARY_DIAGNOSIS_KIDNEY
Look back to the beginning of CORR (1981) to find primary cause of ESRD.
3. Dialysis modality: Hemodialysis, Peritoneal Dialysis, Other, Pre-emptive/Missing, N(%)
(Appendix D)
CORR Dataset: RECIPIENT_TREATMENT
- Variable: TREATMENT_CODE
Note: For patients with Missing dialysis modality (assumed to be pre-emptive recipients), look
back for evidence of chronic dialysis codes and re-classify these patients as HD or PD (see
codes in Appendix B). For duplicate codes (G333, H540, H740), classify as HD.
4. Donor type: Living, Deceased, Unknown/Missing, N(%)
CORR Dataset: TRANSPLANTED_KIDNEY
- Variable: DONOR_TYPE_CODE
Donor type
Living

Deceased
Unknown

CORR: DONOR_TYPE_CODE
Parent
Sibling
Offspring
Other relative
Other living unrelated
Spouse
Anonymous/altruistic
Domino donor
Paired
Deceased donor
Unknown/Out-of-country transplant

Code
02
03
04
05
06
07
10
12
15
01
98

Observed in the first 60 days of the index date – Kidney-related factors (CIHI-DAD,
OHIP) (Table 2):
Record categorical number (%) for the following variables (Cohort A [KTx] only):
1. Delayed graft function: At least one code for dialysis appearing in the first 7 days after the
index date (see Appendix B for dialysis codes), N(%)
2. Primary renal allograft non-function: At least three codes for dialysis on three different days
with at least one code appearing in the first 7 days after the index date, in the 8-30 days after
the index date, and in the 31-60 days after the index date (see Appendix B for dialysis
codes), N(%)
Look back 3 years from index date (CIHI-DAD, OHIP) (Table 2):
CIHI-DAD
Diagnosis Type (dxtype)
All (alldx)
Record categorical number (%) for the following variables unless otherwise stated for all 3
cohorts:
Co-morbidities:
1. Coronary artery disease (CAD) without angina (CIHI-DAD, OHIP)
2. Myocardial infarction (CIHI-DAD)
3. Percutaneous coronary intervention (PCI) (CIHI-DAD, OHIP)
4. Coronary artery bypass graft (CABG) surgery (CIHI-DAD, OHIP)
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5. Heart failure (CIHI-DAD, OHIP)
6. Hypertension (CIHI-DAD, OHIP): Define as evidence of two OHIP claims for hypertension
OR one hospitalization with a diagnosis of hypertension within the three-year look-back
window
7. Diabetes (CIHI-DAD, OHIP): Define as evidence of two OHIP claims for diabetes OR one
hospitalization with a diagnosis of diabetes within the three-year look-back window
8. Stroke/TIA (CIHI-DAD)
Cardiac testing (a recipient can have ≥1 test/visit in the 3-year look-back window):
1. Carotid ultrasound (CIHI-DAD, OHIP)
2. Coronary angiogram (CIHI-DAD, OHIP)
3. Echocardiography (CIHI-DAD, OHIP)
4. Holter monitoring (CIHI-DAD, OHIP)
5. Stress test (CIHI-DAD, OHIP)
Variable look-back window (CORR) (Table 2):
Record mean (with standard deviation), median (with interquartile range), minimum,
maximum, and/or categorical number (%) for the following variables as indicated (Cohort A
[KTx] only):

Outcome
Definitions
(Table 3a,
Table 3b,
Table 3c)
(Appendix E)

1. Time on dialysis prior to transplantation date: Years, mean±SD, median (IQR), minimum,
maximum.
CORR Dataset: RECIPIENT_TREATMENT
- Variable: TREATMENT_DATE ≠171 for first date
- If 171 is the first date, then assume pre-emptive transplant (i.e. Years on dialysis = 0)
- Calculation: Time on dialysis (years) = ([Treatment_Date] & [Treatment_Code] “171”) –
([Treatment Date] & [Treatment Code] “Dialysis Codes in Appendix D”)
Outcomes
CIHI-DAD (Jan 1991 – Dec 2012)
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Diagnosis Type (dxtype)
Most responsible diagnosis (M)
All (alldx) (for 30-day outcomes)
Study period
Prior to 2002 fiscal year à INCLUDE ICD-9 CODES in Appendix E
From 2002 fiscal year and onwards à INCLUDE ICD-10 CODES in Appendix E
Include suspected/questionable diagnoses?
No
Reference date
Do include index date in look-forward period (start at index)
Include abandoned procedures?
No
OHIP (July 1991 – Dec 2012)
Claim Type
Non-lab claims
Code Types
Feecodes à INCLUDE FEECODES in Appendix E
Diagnosis codes à INCLUDE DIAGNOSIS CODES in Appendix E
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Primary outcome (CIHI-DAD, OHIP) (Table 3a):
1. Composite of death or first major adverse cardiovascular event (MACE) within 3 years of
index date (myocardial infarction, percutaneous coronary intervention, coronary artery bypass
graft surgery, ischemic stroke). Use codes defined in Appendix E
For each cohort era, report the number of events that occurred in the follow-up period within
that cohort (i.e. not the number of events that occurred that era. For example, a new kidneyonly transplant recipient receives their transplant in 1995 and enters the 1994-1997 cohort. If
this patient has a stroke in 1998, then the cardiovascular event is reported in the 3-year
outcomes of the 1994-1997 cohort.)
Secondary outcomes at 3 years (CIHI-DAD, OHIP) (Table 3b):
1. Death within 3 years of index date
2. First major adverse cardiovascular event within 3 years of index date censored for death
3. Major adverse cardiovascular event by type within 3 years of index date (censor for death):
Here, the denominator is the total number of recipients in each cohort era
i) Myocardial infarction
ii) Percutaneous coronary intervention
iii) Coronary artery bypass graft surgery
iv) Ischemic stroke
4. Cardiac testing by type within 3 years of index date:
i) Carotid ultrasound
ii) Coronary angiogram
iii) Echocardiography
iv) Holter monitoring
v) Stress test
Secondary outcomes at 30 days (CIHI-DAD, OHIP) (Table 3c):
CIHI-DAD
Diagnosis Type (dxtype)
All (alldx)
5. 30-day cumulative incidence of myocardial infarction
6. 30-day cumulative incidence of ischemic stroke
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Analysis Plan
See Appendix F for Output Tables.
1) Cohort selection (Table 1a, Table 1b, Table 1c): Apply inclusion and exclusion criteria to select the study
cohorts. For Cohort B (GP), match to the kidney transplant recipients as described above. Provide the final
cohort number by year.
2) Baseline characteristics (Table 2a, Table 2b, Table 2c): Provide frequencies and descriptive
characteristics for baseline characteristics for the cohorts accrued in each era of the study period.
Report % missing data for each variable, as indicated.
Report categorical variables as proportions. Report continuous variables as means with standard deviations
for data that is normally distributed or medians with interquartile ranges for skewed data.
Compare cohort characteristics, on an era basis, using the Chi-square test.
3) Primary outcome (Table 3a): For each era of the study period, report the number of recipients in that
cohort era (i.e. got their kidney transplant that year), number of recipients from that cohort era who have
evidence of either death or first major adverse cardiovascular event during the first 3 years of follow-up
(myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, ischemic
stroke), the 95% confidence limits for the incidence rate (Wilson score method), the total person-years of
follow-up (censoring for the outcome, emigration, or end of follow-up), and the event rate per 100 personyears of follow-up. Repeat the analysis for matched Cohort B (GP).
For Cohort A (KTx) only:
i) Repeat the primary analysis using the exponential equation.
ii) Report the median [IQR] time to first event in years for each era.
iii) Breakdown of the type of event within 3 years of index date (death, myocardial infarction, percutaneous
coronary intervention, coronary artery bypass graft surgery, ischemic stroke). Sum of each type should equal
the total number of events for each cohort era. Sum of the proportions for each cohort era should be 1.
iv) Stratify the primary analyses by age (<65 vs. ≥65), sex (female, male), and donor type (living donor,
deceased donor). Report the number of events, the cumulative incidence, the 95% confidence limits, the total
person-years of follow-up, and the event rate per 100 person-years of follow-up.
v) Calculate the incidence rate and 95% confidence limits for each era for the following time periods after
transplantation using Poisson models: 0-3 months, 4-12 months, 13-36 months.
6) Secondary outcomes at 3 years (Table 3b):
Report the number of events, the cumulative incidence, the 95% confidence limits, the total person-years of
follow-up, and the event rate per 100 person-years of follow-up for all 3 cohorts.
a) Death within 3 years of index date
b) First major adverse cardiovascular event within 3 years of index date
For Cohort A (KTx) only:
c) Major adverse cardiovascular event by type within 3 years of index date:
Here, the denominator is the total number of recipients in each cohort era
i) Myocardial infarction
ii) Percutaneous coronary intervention
iii) Coronary artery bypass graft surgery
iv) Ischemic stroke
d) Cardiac testing by type within 3 years of index date:
i) Carotid ultrasound
ii) Coronary angiogram
iii) Echocardiography
iv) Holter monitoring
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v) Stress test
Compare the primary outcome, on an annual basis, using the Cochrane-Armitage test for linear trend. Use
joinpoint regression to identify changes in linear slope.
7) Secondary outcomes at 30 days (Table 3c): To assess perioperative cardiovascular complications,
report the total number of events, the cumulative incidence, and the 95% confidence limits for Cohort A (KTx)
only:
i) Myocardial infarctions within 30 days of the index date
ii) Ischemic strokes within 30 days of the index date

Tables:
Table 1a: Cohort Selection of Kidney Transplant Recipients
Table 1b: Cohort Selection of General Population
Table 1c: Cohort Selection of Chronic Kidney Disease Patients
Table 2a: Baseline Characteristics of Kidney Transplant Recipients by Era
Table 2b: Baseline Characteristics of General Population by Era
Table 2c: Baseline Characteristics of Chronic Kidney Disease Patients by Era
Table 3a: Primary Outcome at 3 Years
Table 3b: Secondary Outcomes at 3 Years
Table 3c: Secondary Outcomes Short and Long-term
Appendices:
Appendix A: Exclusion Codes
Appendix B: Baseline Characteristics Codes
Appendix C: CORR Codes for Primary Cause of End-Stage Renal Disease
Appendix D: CORR Codes for Treatment Codes for Dialysis
Appendix E: Diagnostic Codes for Outcome Variables
Appendix F: Output Table
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Appendix A: Exclusion Codes
Exclusion Variable

Databases

Codes
a

Non-Ontario resident

PRCDDABLK (using %getdemo)

Transplant - renal

CIHI-DAD:
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Include suspected/questionable diagnoses?
No

Dialysis

OHIP:
Claim Type
NONLAB
CIHI-DAD:
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Include suspected/questionable diagnoses?
No
OHIP:
Claim Type
NONLAB

Chronic kidney
disease

a

CIHI-DAD:
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Include suspected/questionable diagnoses?
No

%getdemo is a combination of RPDB and PCCFyyyy datasets

PR ≠ 35
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Appendix B: Baseline Characteristics Codes
Baseline
Characteristics

Database(s)

Age

RPDB

Sex

RPDB

Race

CORR Dataset: RECIPIENT
- Variable: RACIAL_ORIGIN_CODE

Income quintile

PSTLYEAR (using %getdemo)

Rural location

PSTLYEAR (using %getdemo)

Kidney-related
Factors

Database

Date of transplant

CORR Dataset: RECIPIENT_TREATMENT
- Variable: TREATMENT_CODE = 171
- Variable: TREATMENT_DATE
- Variable: TRANSPLANTED_ORGAN_TYPE_CODE[1-3]
CORR Dataset: RECIPIENT_TREATMENT
- Variable: PRIMARY_DIAGNOSIS_KIDNEY

Cause of end-stage
renal disease
Donor type

CORR Dataset: TRANSPLANTED_KIDNEY
- Variable: DONOR_TYPE_CODE

Dialysis modality

CORR Dataset: RECIPIENT_TREATMENT
- Variable: TREATMENT_CODE

Dialysis vintage

CORR Dataset: RECIPIENT_TREATMENT
- Variable: TREATMENT_DATE
CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Diagnosis Type (dxtype)
All (alldx)
Include suspected/questionable diagnoses?
No

Dialysis

Codes

Codes

See Appendix C

See Appendix D

OHIP
Claim Type
NONLAB

Co-morbidities

Database(s)

Coronary artery
disease without
angina

CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Diagnosis Type (dxtype)

Codes
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All (alldx)
Include suspected/questionable diagnoses?
No

Myocardial infarction

Percutaneous
coronary intervention

Coronary artery
bypass graft surgery

Heart failure

Hypertension

OHIP
Claim Type
NONLAB
CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Diagnosis Type (dxtype)
All (alldx)
Include suspected/questionable diagnoses?
No
CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Include suspected/questionable diagnoses?
No
OHIP
Claim Type
NONLAB
CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Include suspected/questionable diagnoses?
No
OHIP
Claim Type
NONLAB
CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Diagnosis Type (dxtype)
All (alldx)
Include suspected/questionable diagnoses?
No
OHIP
Claim Type
NONLAB
CIHI-DAD
Source
All
Institution types
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Acute care (insttype = ‘AP’ or ‘AT’)
Diagnosis Type (dxtype)
All (alldx)
Include suspected/questionable diagnoses?
No
OHIP
Claim Type
NONLAB

Diabetes

Patients with hypertension are those that have evidence
of two OHIP claims for hypertension OR one
hospitalization with a diagnosis of hypertension within the
three-year look-back window.
CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Diagnosis Type (dxtype)
All (alldx)
Include suspected/questionable diagnoses?
No
OHIP
Claim Type
NONLAB

Stroke/Transient
ischemic attack (TIA)

Cardiac Testing
Carotid ultrasound

Patient with diabetes are those that have evidence of two
OHIP claims for diabetes OR one hospitalization with a
diagnosis of diabetes within the three-year look-back
window.
CIHI-DAD
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Diagnosis Type (dxtype)
All (alldx)
Include suspected/questionable diagnoses?
No
Database(s)
CIHI-DAD:
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Include suspected/questionable diagnoses?
No
OHIP:
Claim Type
NONLAB

Codes
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Coronary angiogram

Echocardiography

Holter monitoring

Stress test

CIHI-DAD:
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Include suspected/questionable diagnoses?
No
OHIP:
Claim Type
NONLAB
CIHI-DAD:
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Include suspected/questionable diagnoses?
No
OHIP:
Claim Type
NONLAB
CIHI-DAD:
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Include suspected/questionable diagnoses?
No
OHIP:
Claim Type
NONLAB
CIHI-DAD:
Source
All
Institution types
Acute care (insttype = ‘AP’ or ‘AT’)
Include suspected/questionable diagnoses?
No
OHIP:
Claim Type
NONLAB
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Appendix C: CORR Codes for Primary Cause of End-Stage Renal Disease
Glomerulonephritis/Autoimmune Diseases
05

Mesangial proliferative glomerulonephritis

06

Minimal lesion glomerulonephritis

07

Post-strep glomerulonephritis

08

Rapidly progressive glomerulonephritis

09

Focal glomerulosclerosis - adults

10
11
12

Glomerulonephritis, histologically NOT examined
Severe nephrotic syndrome with focal sclerosis (paed.)
IgA nephropathy - proven by immunofluorescence (not code 85)

13

Dense deposit disease - proven by immunofluorescence and/or electron microscopy (MPGN type II)

14

Membranous nephropathy

15

Membranoproliferative mesangiocapillary glomerulonephritis (MPGN type I)

16

Idiopathic crescentic glomerulonephritis (diffuse proliferative)

17

17 - Congenital Nephrosis/Cong.Nephrotic Syndrome (Paed.)

19

Glomerulonephritis, histologically examined - specify

73

Polyarteritis

74

Wegener’s granulomatosis

84

Lupus erythematosus

85

Henoch-Schõnlein purpura

86

Goodpasture syndrome

88

Hemolytic uremic syndrome (Moschcowitz syndrome)

Cystic Kidney Disease
40

Cystic kidney disease, type unspecified

41

Polycystic kidneys, adult type (dominant)

42

Polycystic kidneys, infantile and juvenile types (recessive)

43

Medullary cystic disease, including nephronophthisis

49

Cystic kidney disease, other type - specify

Diabetes
80

Diabetic nephropathy associated with type 1

81

Diabetic nephropathy associated with type 2

Renal Vascular Disease
70

Renal vascular disease, type unspecified

71

Malignant hypertension (no primary renal disease)

72

Renal vascular disease due to hypertension (no primary renal disease)

79

Renal vascular disease, classified (nephrosclerosis, renal vascular thrombosis)

Other
20
21
22

Pyelonephritis/interstitial nephritis, cause not specified
Pyelonephritis/interstitial nephritis associated with neurogenic bladder
Pyelonephritis/interstitial nephritis due to congenital obstructive uropathy with or without
vesicoureteric reflux
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23

Pyelonephritis/interstitial nephritis due to acquired obstructive uropathy - specify

24

Pyelonephritis/interstitial nephritis due to vesicoureteric reflux without obstruction

25

Pyelonephritis/interstitial nephritis due to urolithiasis

29

Pyelonephritis, other causes

30

Nephropathy caused by drugs or nephrotoxic agents, cause not specified

31

Nephropathy due to analgesic drugs

32

Nephropathy due to cisplatin

33

Nephropathy due to Cyclosporin A

39

Nephropathy caused by other specific drug - specify

50

Hereditary familial nephropathy, type unspecified

51

Hereditary nephritis with nerve deafness (Alport syndrome)

52

Cystinosis

53

Oxalosis

54

Fabry disease

55

DRASH syndrome

56

Sickle cell nephropathy

57

Wilms’ tumour

58

Posterior urethral valves

59

Hereditary nephropathy, other - specify

60

Congenital renal hypoplasia - specify

61

Oligomeganephronic hypoplasia

62

Segmental renal hypoplasia (Ask-Upmark kidney)

63

Congenital renal dysplasia with or without urinary tract malformation

66

Syndrome of agenesis of abdominal muscles (prune belly syndrome)

78

Atheroembolic renal disease

82

Multiple myeloma

83

Amyloid

87

Scleroderma

89

Multi-system disease, other - specify

90

Cortical or acute tubular necrosis

91

Tuberculosis

92

Gout

93

Nephrocalcinosis and hypercalcemic nephropathy

94

Balkan nephropathy

95

Kidney tumour

96

Traumatic or surgical loss of kidney

97

HIV nephropathy

99

Other identified renal disorders - specify

Unknown
00

Chronic renal failure - etiology uncertain

98

Unknown
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Appendix D: CORR Codes for Treatment Codes for Dialysis
Hemodialysis
111

1 - Acute Care Hospital, 1 - Conventional Haemodialysis, 1 - Total Care

112

1 - Acute Care Hospital, 1 - Conventional Haemodialysis, 2 - Limited Self Care

113

1 - Acute Care Hospital, 1 - Conventional Haemodialysis, 3 - Total Self Care

121

1 - Acute Care Hospital, 2 - Short Daily Haemodialysis, 1 - Total Care

122

1 - Acute Care Hospital, 2 - Short Daily Haemodialysis, 2 - Limited Self Care

123

1 - Acute Care Hospital, 2 - Short Daily Haemodialysis, 3 - Total Self Care

131

1 - Acute Care Hospital, 3 - Slow Nocturnal Haemodialysis, 1 - Total Care

132

1 - Acute Care Hospital, 3 - Slow Nocturnal Haemodialysis, 2 - Limited Self Care

133

1 - Acute Care Hospital, 3 - Slow Nocturnal Haemodialysis, 3 - Total Self Care

211

2 - Chronic Care Hospital, 1 - Conventional Haemodialysis, 1 - Total Care

221

2 - Chronic Care Hospital, 2 - Short Daily Haemodialysis, 1 - Total Care

231

2 - Chronic Care Hospital, 3 - Slow Nocturnal Haemodialysis, 1 - Total Care

311

3 - Community Centre, 1 - Conventional Haemodialysis, 1 - Total Care

312

3 - Community Centre, 1 - Conventional Haemodialysis, 2 - Limited Self Care

313

3 - Community Centre, 1 - Conventional Haemodialysis, 3 - Total Self Care

321

3 - Community Centre, 2 - Short Daily Haemodialysis, 1 - Total Care

322

3 - Community Centre, 2 - Short Daily Haemodialysis, 2 - Limited Self Care

323

3 - Community Centre, 2 - Short Daily Haemodialysis, 3 - Total Self Care

331

3 - Community Centre, 3 - Slow Nocturnal Haemodialysis, 1 - Total Care

332

3 - Community Centre, 3 - Slow Nocturnal Haemodialysis, 2 - Limited Self Care

333

3 - Community Centre, 3 - Slow Nocturnal Haemodialysis, 3 - Total Self Care

413

4 - Home, 1 - Conventional Haemodialysis, 3 - Total Self Care

423

4 - Home, 2 - Short Daily Haemodialysis, 3 - Total Self Care

433

4 - Home, 3 - Slow Nocturnal Haemodialysis, 3 - Total Self Care

Peritoneal Dialysis
141

1 - Acute Care Hospital, 4 - CAPD, 1 - Total Care

151

1 - Acute Care Hospital, 5 - APD, 1 - Total Care

152

1 - Acute Care Hospital, 5 - APD, 2 - Limited Self Care

241

2 - Chronic Care Hospital, 4 - CAPD, 1 - Total Care

242

2 - Chronic Care Hospital, 4 - CAPD, 2 - Limited Self Care

251

2 - Chronic Care Hospital, 5 - APD, 1 - Total Care

252

2 - Chronic Care Hospital, 5 - APD, 2 - Limited Self Care

443

4 - Home, 4 - CAPD, 3 - Total Self Care

453

4 - Home, 5 - APD, 3 - Total Self Care

Other
060

0 - Treatment-dependent Locations, 6 - PD combined with HD, 0 - Other
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Appendix E: Diagnostic Codes for Outcome Variables
CIHI-DAD
Diagnosis Type (dxtype)
Most responsible diagnosis (M)
(except where indicated e.g. alldx for 30-day outcome of acute MI and ischemic stroke)
Outcome Variable

Database(s)

Codes

Death

RPDB

Vital status field

Myocardial infarction

CIHI–diagnostic

Ischemic stroke

CIHI-diagnostic

Percutaneous coronary
intervention

CIHI-procedure
OHIP-procedure

Coronary artery bypass graft
surgery

CIHI-procedure
OHIP-procedure

Cardiac testing

CIHI-procedure
OHIP-procedure

Appendix F: Outcome Tables

See Appendix B
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Appendix 2: STROBE checklist.(34)
Item
Recommendation
No
(a) Indicate the study’s design with a commonly used
term in the title or the abstract
Title and
1
abstract
(b) Provide in the abstract an informative and balanced
summary of what was done and what was found
Introduction
Background and
Explain the scientific background and rationale for the
2
rationale
investigation being reported
State specific objectives, including any pre-specified
Objectives
3
hypotheses
Methods
Study design
4
Present key elements of study design early in the paper
Describe the setting, locations, and relevant dates,
Setting
5
including periods of recruitment, exposure, follow-up,
and data collection
(a) Give the eligibility criteria, and the sources and
methods of selection of participants. Describe methods
of follow-up
Participants
6
(b) For matched studies, give matching criteria and
number of exposed and unexposed
Clearly define all outcomes, exposures, predictors,
Variables
7
potential confounders, and effect modifiers. Give
diagnostic criteria, if applicable
For each variable of interest, give sources of data and
Data sources/
details of methods of assessment (measurement).
8
measurement
Describe comparability of assessment methods if there
is more than one group
Bias
9
Describe any efforts to address potential sources of bias
Study size

10

Quantitative
variables

11

Statistical
methods

12

Explain how the study size was arrived at
Explain how quantitative variables were handled in the
analyses. If applicable, describe which groupings were
chosen and why
(a) Describe all statistical methods, including those used
to control for confounding
(b) Describe any methods used to examine subgroups

Reported in
Section
Abstract
Abstract

Introduction
Introduction
Methods
Methods

Methods
Methods
Methods
Appendix 3
Methods
Appendix 3
Methods
Methods
Figure 1
Methods
Methods
Methods
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and interactions
(c) Explain how missing data were addressed
(d) If applicable, explain how loss to follow-up was
addressed
(e) Describe any sensitivity analyses

Methods
Not applicable
Not applicable

Results

Participants

Descriptive data

Outcome data

Main results

Other analyses

13

14

15

16

17

(a) Report numbers of individuals at each stage of
study—e.g. numbers potentially eligible, examined for
eligibility, confirmed eligible, included in the study,
completing follow-up, and analyzed
(b) Give reasons for non-participation at each stage
(c) Consider use of a flow diagram
(a) Give characteristics of study participants (e.g.
demographic, clinical, social) and information on
exposures and potential confounders
(b) Indicate number of participants with missing data for
each variable of interest
(c) Summarize follow-up time (e.g. average and total
amount)
Report numbers of outcome events or summary
measures over time
(a) Give unadjusted estimates and, if applicable,
confounder-adjusted estimates and their precision (e.g.
95% confidence interval). Make clear which
confounders were adjusted for and why they were
included
(b) Report category boundaries when continuous
variables were categorized
(c) If relevant, consider translating estimates of relative
risk into absolute risk for a meaningful time period
Report other analyses done—e.g. analyses of subgroups
and interactions, and sensitivity analyses

Results
Figure 1
Figure 1
Figure 1
Results
Table 2
Table 3
Table 2
Results
Results
Table 4
Table 6
Results
Table 4
Table 6
Table 1
Not applicable
Results

Discussion
Key results

18

Limitations

19

Interpretation

20

Summarize key results with reference to study
objectives
Discuss limitations of the study, taking into account
sources of potential bias or imprecision. Discuss both
direction and magnitude of any potential bias
Give a cautious overall interpretation of results

Discussion
Discussion
Discussion
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Generalizability

21

considering objectives, limitations, multiplicity of
analyses, results from similar studies, and other relevant
evidence
Discuss the generalizability (external validity) of the
study results

Discussion

Other information
Funding

22

Give the source of funding and the role of the funders
for the present study and, if applicable, for the original
study on which the present article is based

Disclosure
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Appendix 3: Databases and coding definitions.
Variable
Database
Codes
Inclusion/Exclusion Criteria
Kidney
CIHI-diagnostic
ICD-9: V42.0, 996.81
transplantation
CIHI-diagnostic
ICD-10: N16.5, T86.1, Z94.0

Dialysis

Chronic kidney
disease

CIHI-procedure

CCP: 67.43, 67.5

CIHI-procedure

CCI: 1PC85

OHIP-procedurea

OHIP: E762, E769, E771, G347, G348, G408, G409, G412,
S434, S435, Z631

CORR
CIHI-diagnostic

Treatment_code: 171, 181
Transplanted_organ_type_code [1-3]: 10, 11, 12, 18, 19
ICD-9: V45.1, V56.0, V56.8, 996.73

CIHI-diagnostic

ICD-10: T82.4, Y60.2, Y61.2, Y62.2, Y84.1, Z49, Z99.2

CIHI-procedure

CCP: 51.27, 51.42, 51.43, 51.95, 66.98

CIHI-procedure

CCI: 1JM76NC, 1JM76NCXXN, 1KG76MZXXA,
1KG76MZXXN, 1KY76, 1PZ21, 1OT53DATS,
1OT53HATS, 1OT53LATS, 1SY55LAFT, 7SC59QD

OHIP-procedurea

OHIP: G082, G083, G085, G090, G091, G092, G093, G094,
G095, G096, G099, G294, G295, G323, G324, G325, G326,
G327, G330, G331, G332, G333, G336, G860, G861, G862,
G863, G864, G865, G866, H540, H740, R825, R826, R827,
R833, R840, R841, R843, R848, R849, R850, R851, R852,
R853, R854, R885, R941, R942, R943, R944, R945, R946,
Z450, Z451, Z452
ICD-9: 250.4, 403.0, 403.1, 403.9, 404.0, 404.1, 404.9, 585,
586, 588.8, 588.9

CIHI-diagnostic

CIHI-diagnostic

ICD-10: E10.2, E11.2, E13.2, E14.2, I12, I13, N08, N18, N19

OHIP-diagnostic

OHIP: 403, 585

70

Baseline Characteristics - Demographics
Age, Sex,
RPDB
Socioeconomic
status, Rural
location
Race
CORR
Racial_origin_code:
Caucasian: 01
Asian: 02
African-American: 03
Indian: 05
Other: 08, 09, 10, 11, 99
Unknown: 98
Baseline Characteristics – Kidney-Related Characteristics
Transplant date
CORR
Cause of ESRD
CORR
Primary_diagnosis_kidney:
Glomerulonephritis/Auto-immune disease: 05, 06, 07, 08, 09,
10, 11, 12, 13, 14, 15, 16, 17, 19, 73, 74, 84, 85, 86, 88
Diabetes: 80, 81
Cystic kidney disease: 40, 41, 42, 43, 49
Renal vascular disease: 70, 71, 72, 79
Other: 20, 21, 22, 23, 24, 25, 29, 30, 31, 32, 33, 39, 50, 51, 52,
53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 66, 78, 82, 83, 87,
89, 90, 91, 92, 93, 94, 95, 96, 97, 99
Unknown: 00, 98
Donor type
CORR
Donor_type_code:
Living: 02, 03, 04, 05, 06, 07, 10, 12, 15
Deceased: 01
Unknown/Out-of-country transplant: 98
Dialysis modality CORR
Treatment_code:
Hemodialysis: 111, 112, 113, 121, 122, 123, 131, 132, 133,
211, 221, 231, 311, 312, 313, 321, 322, 323, 331, 332, 333,
413, 423, 433
Peritoneal dialysis: 141, 151, 152, 241, 242, 251, 252, 443,
453
Other: 060
Dialysis vintage
CORR
Treatment_date
Dialysis
CIHI-procedure
CCP: 51.95, 66.98
CIHI-procedure

CCI: 1PZ21
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OHIP-procedurea

OHIP: G082, G083, G085, G090, G091, G092, G093, G094,
G095, G096, G294, G295, G323, G325, G326, G330, G331,
G332, G333, G860, G861, G862, G863, G864, G865, G866,
H540, H740, R849
Baseline Characteristics – Co-morbidities
Coronary artery
CIHI-diagnostic
ICD-9: 410, 411, 412
disease
CIHI-diagnostic
ICD-10: I21, I22, T82.2, Z95.5

Hypertensionb

Diabetes

b

Myocardial
infarction
PCI

CABG surgery

CIHI-procedure

CCP: 48.01, 48.02, 48.03, 48.04, 48.05, 48.1, 48.2, 48.3

CIHI-procedure

CCI: 1IJ50, 1IJ76

OHIP-diagnostic

OHIP: 410, 412

OHIP-procedurea
CIHI-diagnostic

OHIP: E646, E651, E652, E654, E655, G298, R741, R742,
R743, Z434, Z448
ICD-9: 401, 402, 403, 404, 405

CIHI-diagnostic

ICD-10: I10, I11, I12, I13, I15

OHIP-diagnostic
CIHI-diagnostic

OHIP: 401, 402, 403
ICD-9: 250

CIHI-diagnostic

ICD-10: E10, E11, E13, E14

OHIP-diagnostic

OHIP: 250

OHIP-procedurea
CIHI-diagnostic

OHIP: K029, K030, Q040
ICD-9: 410

CIHI-diagnostic
CIHI-procedure

ICD-10: I21, I22
CCP: 48.02, 48.03, 48.09

CIHI-procedure

CCI: 1IJ50, 1IJ54GQAZ, 1IJ57GQ

OHIP-procedurea
CIHI-procedure

OHIP: G262, G298, Z434
CCP: 48.11, 48.12, 48.13, 48.14, 48.15, 48.16, 48.17, 48.19

CIHI-procedure

CCI: 1IJ76
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Heart failure

Stroke/TIA

OHIP-procedure
CIHI-diagnostic

OHIP: E645, E646, E652, E654, R742, R743
ICD-9: 425, 428, 514, 518.4

CIHI-diagnostic

ICD-10: I25.5, I50.0, I50.1, I50.9, J81

CIHI-procedure

CCP: 49.61, 49.62, 49.63, 49.64

CIHI-procedure

CCI: 1HP53, 1HP55, 1HZ53GRFR, 1HZ53LAFR,
1HZ53SYFR

OHIP-diagnostic

OHIP: 428

OHIP-procedurea
CIHI-diagnostic

OHIP: R701, R702, Z429
ICD-9: 362.3, 430, 431, 432, 434, 435, 436

CIHI-diagnostic

ICD-10: G45.0, G45.1, G45.2, G45.3, G45.8, G45.9, H34.0,
H34.1, I60.0, I60.1, I60.2, I60.3, I60.4, I60.5, I60.6, I60.7,
I60.9, I61, I62, I63.0, I63.1, I63.2, I63.3, I63.4, I63.5, I63.8,
I63.9, I64
Baseline Characteristics – Cardiovascular Investigations
Holter monitor
CIHI-procedure
CCP: 03.54
CIHI-procedure

CCI: 2HZ24JAKH

OHIP-procedurea

OHIP: G311, G320, G647, G648, G649, G650, G651, G652,
G653, G654, G655, G656, G657, G658, G659, G660, G661,
G682, G683, G684, G685, G686, G687, G688, G689, G690,
G692, G693
CCP: 02.82

Echocardiography CIHI-procedure

Stress test

CIHI-procedure

CCI: 3IP30

OHIP-procedurea
CIHI-procedure

OHIP: G560, G561, G562, G566, G567, G568, G570, G571,
G572, G574, G575, G576, G577, G578, G581
CCP: 03.41, 03.42, 03.43, 03.44, 06.05

CIHI-procedure

CCI: 2HZ08, 3IP70

OHIP-procedurea

OHIP: G111, G112, G174, G315, G319, G582, G583, G584,
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Coronary
angiogram

Carotid
ultrasound

CIHI-procedure

J607, J608, J609, J666, J807, J808, J809, J866
CCP: 48.92, 48.93, 48.94, 48.95, 48.96, 48.97, 48.98

CIHI-procedure

CCI: 3IP10, 3IS10

OHIP-procedurea
CIHI-procedure

OHIP: G297, G509
CCP: 02.81

CIHI-procedure

CCI: 3JE30, 3JG30

OHIP-procedurea
Outcome Measurements
Death (68)
RPDB
Myocardial
infarction (69,70)

CIHI-diagnostic

OHIP: J190, J191, J201, J490, J491, J492, J501
Validityc,d
Vital status field
Sensitivity: 94%
PPV: 100%
As above
For ICD-9 codes:
Sensitivity: 89%
PPV: 90%
For ICD-10 codes:e
Sensitivity: 89%
PPV: 87%
For CCI codes:
PPV: 94-96%

PCI (71)

CIHI-procedure

As above

CABG (71)

OHIP-procedurea
CIHI-procedure

As above

For CCI codes:
PPV: 97-98%

OHIP-procedurea
CIHI-diagnostic

ICD-9: 434, 436

For ICD-9 codes:
PPV: 86-92%

Ischemic stroke
(72)

CIHI-diagnostic
Cardiovascular
investigation

CIHI-procedure

ICD-10: H34.1, I63.0, I63.1, I63.2,
I63.3, I63.4, I63.5, I63.8, I63.9, I64
As above

OHIP-procedurea
a
Approximately 95% of Ontario physicians operate under the fee for service payment structure of the
Ontario Health Insurance Plan (OHIP). The sensitivity and positive predictive value of these procedure
codes is expected to be high, as shown with other service payments.(73) Other studies have reported the
value of using physician billing data in combination with other administrative healthcare data to
improve the identification of relevant procedures.(74)

74
b

Defined as evidence of 2 OHIP claims or 1 hospitalization with a diagnostic claim within the 3-year
look-back window.
c
Information regarding specificity and negative predictive value is omitted. In almost all instances
these parameters were high and precise because of the low underlying prevalence of the diagnoses or
procedures in the dataset.
d
Validation performed against the following reference standards: chart review,(68) patient registry,(69)
chart abstraction and recoding.(70–72) Diagnostic conditions were considered present in the discharge
abstract for any hospitalization if it was listed as the primary reason for the majority of length of
hospital stay.
e
Added ICD-10 code I22 (subsequent myocardial infarction).
Abbreviations: CABG, coronary artery bypass graft; CCI, Canadian Classification of Health
Interventions; CCP, Canadian Classification of Diagnostic, Therapeutic and Surgical Procedures; CIHI,
Canadian Institute for Health Information; CORR, Canadian Organ Replacement Register; ESRD, endstage renal disease; ICD-9; International Classification of Diseases, 9th Revision; ICD-10, International
Classification of Diseases, 10th Revision; OHIP, Ontario Health Insurance Plan; PCI, percutaneous
coronary intervention; PPV, positive predictive value; RPDB, Registered Persons Database; TIA,
transient ischemic attack.
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